It can be seen from analysis on major blood grouping analyzer-related patent applications published in the 3 years from 2018 to 2021 that benefited from the basically stable original technologies of the industry; domestic enterprises have continuously increased R&D inputs, constantly improved technical innovation capability, made breakthroughs in many technologies, and developed a batch of core components of instruments with independent intellectual property rights through follow-on R&D strategy.

China plans to accelerate the establishment of a tiered healthcare delivery system, focusing on strengthening primary-level medical capacity to manage common and chronic diseases such as hypertension and diabetes, authorities said.

On April 9, 2021, Chemclin Diagnostics Corporation (stock code 688468) successfully listed on SSESTARMarket of the Shanghai Stock Exchange.

Normally, it takes 10-15 years to develop a vaccine because of the complexity of vaccine development. The previous record was a mumps vaccine, which took four years to develop.

SINOPHARM GROUP achieved business revenue of about 456.4 billion yuan, an increase of 7.32% year-on-year.

On March 17th, Jiangsu Bioperfectus Technologies Co., Ltd. signed a strategic cooperation agreement with HUIXIN LABORATORY. Wang Guoqiang, General Manager of Bioperfectus Technologies, Liang Xiaobing, General Manager of HUIXIN LABORATORY, an

Roche announced on the 15th that it will acquire GenMark Diagnostics, a US molecular pathology laboratory manufacturer, for US$1.8 billion.

A total of 64.98 million people have been vaccinated with COVID-19 vaccine, according to the National Health Commission.

Recently, the strategic business matchmaking meeting between Jointown medical devices group co., ltd. and Mindray was held in Shenzhen.

Recently, COVID-19 (SARS-CoV-2) Antigen Test Kit independently developed by Wuhan Easy Diagnosis passed the performance verification of Paul-Ehrlich-Institut in Germany.

Recently, Roche Diagnostics and Yunkang Group officially announced that they had reached further strategic cooperation.

At present, six new COVID-19 antigen (home-use) kits have been authorized for emergency use by BfArM. The certification means that the product can be sold in German supermarkets, and local residents can use the product for self-testing.